Merck, J&J Strike Deal In Arthritis Drugs Dispute

Law360, New York (April 15, 2011, 10:11 PM EDT) -- Merck & Co. Inc. said Friday it will pay Johnson & Johnson $500 million to end a dispute over rights to two arthritis drugs resulting from Merck's merger with Schering-Plough Corp., and that the two companies plan to share marketing rights.

Merck added it would hand J&J's Janssen unit exclusive marketing rights to the drugs Remicade and Simponi in Canada, Central and South America, the Middle East, Africa, and Asia Pacific on July 1, while retaining marketing rights throughout Europe, Russia and Turkey.

The deal ends...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.